Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725558 | 0.88 | FFAR1 (0.57) | FFAR1DGAT1USP30AAK1PRMT5 | |
| SCHEMBL25414529 | 0.87 | FFAR1 (0.46) | FFAR1DGAT1USP30AAK1PRMT5 | |
| SCHEMBL4099087 | 0.85 | FFAR1 (0.57) | FFAR1DGAT1USP30HIF1AGSK3B | |
| SCHEMBL18530455 | 0.84 | FFAR1 (0.54) | FFAR1DGAT1USP30AAK1PRMT5 | |
| SCHEMBL31461820 | 0.83 | FFAR1 (0.53) | FFAR1DGAT1USP30AAK1PRMT5 | |
| SCHEMBL25245752 | 0.83 | FFAR1 (0.53) | FFAR1DGAT1USP30AAK1PRMT5 | |
| SCHEMBL31461761 | 0.83 | FFAR1 (0.53) | FFAR1DGAT1USP30AAK1PRMT5 | |
| SCHEMBL25248137 | 0.83 | FFAR1 (0.53) | FFAR1DGAT1USP30AAK1PRMT5 | |
| SCHEMBL938503 | 0.83 | FFAR1 (0.54) | FFAR1DGAT1GSK3BGSK3AUCHL1 | |
| SCHEMBL30188549 | 0.83 | FFAR1 (0.42) | FFAR1USP30ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737443-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Tanabe Pharma Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4673438-A1 | PROTEOLYSIS-TARGETING CHIMERAS | Tocris Cookson Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2025-09-18 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | AURIGENE DISCOVERY TECH LTD (IN) | 2025-07-29 | — | — | US | disclosed |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2010-05-27 | — | — | US | disclosed |
| EP-2182986-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010041748-A1 | FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | 日本たばこ産業株式会社 (JP) | 2010-04-15 | — | — | WO | disclosed |
| US-7683060-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683060-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2009097233-A9 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | FFAR1 3228/4885DGAT1 2457/4885USP30 2933/4885 |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | FFAR1 3285/4885DGAT1 3569/4885USP30 2065/4885 |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | SIK1, SIK3, SIK2 | FFAR1 2539/4885DGAT1 2055/4885USP30 3439/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | FFAR1 3802/4885DGAT1 3866/4885USP30 878/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | FFAR1 1459/4885DGAT1 1626/4885USP30 942/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | FFAR1 2624/4885DGAT1 4451/4885USP30 3305/4885 |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | FFAR1 3285/4885DGAT1 3569/4885USP30 2065/4885 |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | FFAR1 2643/4885DGAT1 1616/4885USP30 2790/4885 |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | FFAR1 4028/4885DGAT1 3904/4885USP30 167/4885 |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | SMARCC1, SMARCC2, SMARCA2 | FFAR1 3263/4885DGAT1 4859/4885USP30 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.